A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom

Back to Search
Print
Bookmark Trial

NCT00751049

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Aberdeen, Grampian, AB25 2ZD, United Kingdom
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Ocular Hypertension, Open Angle Glaucoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
40 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Unilateral or bilateral primary open angle glaucoma, capsular glaucoma, pigmentary glaucoma or ocular hypertension.

- Open angle glaucoma appearing more than 6 months after cataract surgery is recognized as primary open angle glaucoma. (individuals requiring treatment bilaterally must fulfill eligibility criteria for both eyes.)

- IOP of 22mmHg or higher obtained during the pre-study period.

- Patients currently not treated or on single-drug treatment for the elevated IOP are eligible after a medication free period (wash-out) of:

1. 3 weeks for B-adrenergic antagonists

2. 2 weeks for adrenergic agonists

3. 5 days for cholinergics and oral carbonic anhydrase inhibitors.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- History of acute angle closure.


- Severe trauma at any time.


- Intraocular surgery or argon laser trabeculoplasty within 6 months.


- Current use of contact lenses.


- History of severe dry eye syndrome.


- Ocular inflammation/infection with three months of inclusion.


- Any condition preventing reliable applanation tonometry.


- Unacceptable finding at pre-study ocular examination as specified in the Case Report
Forms.


- In Investigator regards monotherapy insufficient with respect to optic nerve head
and/or visual field status.


- Treatment of elevated IOP with any topical B-adrenergic antagonist regularly for a
period longer than 3 months and/or treatment at any time during 6 months prior to
study start.


- Cardiac failure, sinus bradycardia, second and third degree of atrio-ventricular
block.


- Bronchial asthma, history of bronchial asthma or chronic obstructive pulmonary
disease.


- Having participated in any other clinical study within the last month.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Ocular Hypertension, Open Angle GlaucomaA Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom
NCT00751049
  1. Aberdeen, Grampian
  2. Nottingham, Notts.
  3. Bristol,
  4. Cambridge,
  5. Cardiff,
  6. Dundee,
  7. Liverpool,
  8. London,
  9. London,
  10. Manchester,
  11. Paisley,
  12. Sheffield,
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom
Official Title  ICMJE A 6-Month, Randomized, Double-Masked Comparison of PhXA41 With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension. A Multi-Centre Study in the United Kingdom
Brief Summary Study PhXA41 for its non-inferiority compared with timolol in lowering intra-ocular pressure
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE
  • Ocular Hypertension
  • Open Angle Glaucoma
Intervention  ICMJE
  • Drug: timolol
    One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
  • Drug: PhXA41
    One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
Study Arms  ICMJE
  • Experimental: PhXA41
    Intervention: Drug: PhXA41
  • Active Comparator: timolol
    Intervention: Drug: timolol
Publications * Varma R, Hwang LJ, Grunden JW, Bean GW, Sultan MB. Assessing the efficacy of latanoprost vs timolol using an alternate efficacy parameter: the intervisit intraocular pressure range. Am J Ophthalmol. 2009 Aug;148(2):221-6. doi: 10.1016/j.ajo.2009.02.035. Epub 2009 May 9.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 10, 2008)		294
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE December 1993
Actual Primary Completion Date December 1993   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Unilateral or bilateral primary open angle glaucoma, capsular glaucoma, pigmentary glaucoma or ocular hypertension.
  • Open angle glaucoma appearing more than 6 months after cataract surgery is recognized as primary open angle glaucoma. (individuals requiring treatment bilaterally must fulfill eligibility criteria for both eyes.)
  • IOP of 22mmHg or higher obtained during the pre-study period.

  • Patients currently not treated or on single-drug treatment for the elevated IOP are eligible after a medication free period (wash-out) of:

    1. 3 weeks for B-adrenergic antagonists
    2. 2 weeks for adrenergic agonists
    3. 5 days for cholinergics and oral carbonic anhydrase inhibitors.

Exclusion Criteria:

  • History of acute angle closure.
  • Severe trauma at any time.
  • Intraocular surgery or argon laser trabeculoplasty within 6 months.
  • Current use of contact lenses.
  • History of severe dry eye syndrome.
  • Ocular inflammation/infection with three months of inclusion.
  • Any condition preventing reliable applanation tonometry.
  • Unacceptable finding at pre-study ocular examination as specified in the Case Report Forms.
  • In Investigator regards monotherapy insufficient with respect to optic nerve head and/or visual field status.
  • Treatment of elevated IOP with any topical B-adrenergic antagonist regularly for a period longer than 3 months and/or treatment at any time during 6 months prior to study start.
  • Cardiac failure, sinus bradycardia, second and third degree of atrio-ventricular block.
  • Bronchial asthma, history of bronchial asthma or chronic obstructive pulmonary disease.
  • Having participated in any other clinical study within the last month.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 40 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00751049
Other Study ID Numbers  ICMJE 9200PG005
A6111129
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date September 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP